MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/rmdopen-2023-003795

Медицинская библиотека · RMD open · 2023

Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.

Ladouceur Alexandra, Barnetche Thomas, Mouterde Gael, Tison Alice, Bitoun Samuel, Prey Sorilla, Dutriaux Caroline, Gerard Emilie, Pham-Ledard Anne, Beylot-Barry Marie, Zysman Maeva, Veillon Rémi, Domblides Charlotte, Daste Amaury, Gross-Goupil Marine, Sionneau Baptiste, Lefort Felix, Larroquette Mathieu, Richez Christophe, Truchetet Marie-Elise, Schaeverbeke Thierry, Kostine Marie

Наблюдательное исследованиеМногоцентровое исследованиеСтатьяПеревод в очереди

Аннотация

OBJECTIVE

Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety of ICI rechallenge in this setting. We aimed to assess the rate and clinical features associated with ICI-IA flare/recurrence on ICI rechallenge.

METHODS

We conducted a multicentre observational study including cancer patients with ICI-IA who started a second course of ICI more than 3 months after ICI discontinuation in four French university hospitals. Primary outcome was the frequency of ICI flare/recurrence after ICI rechallenge.

RESULTS

Twenty-three patients were included. At the time of ICI rechallenge, 18 patients reported no symptoms of ICI-IA (78%) and 5 had grade 1 (22%), 11 patients (48%) were not receiving any ICI-IA treatment, 11 (48%) were still on prednisone, 2 (9%) were on conventional synthetic disease-modifying antirheumatic drugs and 1 (4%) on anti-IL-6. ICI-IA flare/recurrence occurred in 12 patients (52%) with a median time of 1 month after ICI rechallenge. ICI-IA phenotype, disease activity and ICI-IA treatment at the time of ICI rechallenge did not differ according to ICI-IA flare/recurrence status.

CONCLUSION

In this first observational study of ICI-IA patients rechallenged with ICI, about half of the patients experienced ICI-IA flare/recurrence with a similar phenotype but occurring earlier than the initial ICI-IA, warranting close monitoring during the first month of retreatment. Risk of flare did not differ according to baseline immunosuppressive treatment at the time of rechallenge.

Для цитирования: Ladouceur Alexandra, Barnetche Thomas, Mouterde Gael, Tison Alice, Bitoun Samuel, Prey Sorilla, Dutriaux Caroline, Gerard Emilie, Pham-Ledard Anne, Beylot-Barry Marie, Zysman Maeva, Veillon Rémi, Domblides Charlotte, Daste Amaury, Gross-Goupil Marine, Sionneau Baptiste, Lefort Felix, Larroquette Mathieu, Richez Christophe, Truchetet Marie-Elise, Schaeverbeke Thierry, Kostine Marie. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study.. RMD open. 2023. DOI: 10.1136/rmdopen-2023-003795.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.